Upexi, Inc. Q2 FY2024 Earnings Call
· Earnings call transcript and AI-powered summary
Upexi Inc. Fiscal Q2 2024 Earnings Summary
- Revenue: $21.8 million, down from $27.3 million in fiscal Q1 2024 and $26.7 million in Q2 2023. The decline was mainly due to lower re-commerce revenue through Amazon and wholesale channels.
- Brand Product Sales: Increased 16.7% sequentially to $7.7 million (from $6.6 million in Q1 2024), emphasizing a strategic focus on higher-margin and recurring revenue streams through subscription-based models.
- Gross Margin: Improved to 38%, up from 31.8% in Q1 2024 and flat compared to Q2 2023. The margin improvement is attributable to a higher percentage of branded product sales.
- Adjusted EBITDA: Positive $29,000 in Q2 2024, a decrease from $750,000 in Q1 2024 and $557,000 in Q2 2023.
- Net Income/Loss: Net loss from continuing operations of $2.4 million in Q2 2024, compared to a $1.4 million loss in Q1 2024 and $2.7 million net income in Q2 2023.
- Cash & Equity: $1.8 million in cash and $25.5 million in total stockholders’ equity as of December 31, 2023.
- Marketing Spend: Sales and marketing expenses declined by 18% YoY and were reduced by $160,000 sequentially, despite continued investment in branded subscription models like VitaMedica, with a 5% MoM subscription revenue growth.
Continue Reading
Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.
Upgrade to ProfessionalContinue Reading
Unlock the full earnings call transcript with speaker labels and formatted dialogue.
Upgrade to Professional